Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 5,622 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -0.28% | 14.21 | 09:11:43 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.25 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 31 | 5,622 | - | 6.46 - 35.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:15:35 | 50 | $ 14.21 | USD |
TG Therapeutics (TGTX) Options Flow Summary
TG Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.2B | 154.42M | - | 233.66M | 12.67M | 0.08 | 173.57 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TG Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.06 | 14.63 | 13.26 | 13.98 | 3,142,884 | 0.15 | 1.07% |
| 1 Month | 15.55 | 15.615 | 13.26 | 14.41 | 2,560,269 | -1.34 | -8.62% |
| 3 Months | 16.10 | 19.0175 | 12.84 | 15.39 | 3,494,651 | -1.89 | -11.74% |
| 6 Months | 6.77 | 22.67 | 6.77 | 14.42 | 5,020,703 | 7.44 | 109.90% |
| 1 Year | 22.22 | 35.67 | 6.46 | 15.90 | 4,786,903 | -8.01 | -36.05% |
| 3 Years | 42.86 | 45.50 | 3.48 | 14.62 | 3,465,857 | -28.65 | -66.85% |
| 5 Years | 8.13 | 56.74 | 3.48 | 16.34 | 2,766,543 | 6.08 | 74.78% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
